PPHE positive on $1.24 billion takeover bid from Israel's Fattal Hotel Group

• The offer values PPHE at £22 per share, totaling approximately $1.24 billion for the London-listed hospitality real estate firm
• PPHE's controlling shareholders Papouchado and Ivesha, who hold about 44% of voting rights, are engaged in the discussions
• Fattal reserves the right to vary the offer terms, including introducing securities or reducing the £22-per-share price, as negotiations proceed

Summary: PPHE Hotel Group Receives $1.24 Billion Takeover Bid from Fattal

Key Transaction Details:

PPHE Hotel Group announced it has received a £920.9 million ($1.24 billion) takeover proposal from Israel's Fattal Hotel Group at £22 per share. The London-listed hospitality real estate firm indicated the offer "fairly values" the business.

Background:

PPHE initiated a strategic review in November, shortly after controlling shareholders Eli Papouchado and Yoav Ivesha—who collectively hold approximately 44% of voting rights—expressed interest in acquiring the company. This proposal from Fattal represents a potential alternative to management's original plans.

Transaction Status:

PPHE confirmed it will engage with major shareholders regarding the offer. Fattal has reserved the right to modify the offer's form or value, potentially introducing securities or reducing the £22-per-share price, indicating the deal structure remains flexible.

Companies Involved:

• PPHE Hotel Group: Amsterdam-headquartered hospitality real estate operator managing European properties under brands including Park Plaza and art'otel
• Fattal Hotel Group: Israeli hotel operator with a portfolio spanning Europe and the Middle East

Market Implications:

The takeover bid represents significant consolidation in the European hospitality sector, potentially creating a larger pan-European hotel operator. The deal would give Fattal expanded access to premium European markets while offering PPHE shareholders liquidity at a valuation management considers fair. The involvement of existing controlling shareholders adds complexity, as they may compete with or support Fattal's offer.

The transaction remains subject to shareholder approval and regulatory processes, with final terms potentially subject to revision.